EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression

Raymond Yan, Tyler Marshall, Atul Khullar, Travis Nagle, Jake Knowles, Mai Malkin, Brittany Chubbs, Jennifer Swainson iD

Therapeutic Advances in Psychopharmacology · 2024-01 · 14

DOI: 10.1177/20451253241231264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 04.03.2024. Verfasst von Raymond Yan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Alberta Dept of Psychiatry.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intravenous (IV) ketamine is a rapid acting antidepressant used primarily for treatment-resistant depression (TRD). It has been suggested that IV ketamine’s rapid antidepressant effects may be partially mediated via improved sleep and changes to the circadian rhythm.

Objectives

This study explores IV ketamine’s association with changes in patient-reported sleep quality and circadian rhythm in an adult population with TRD.

Methods

Adult patients (18–64 years) with TRD scheduled for IV ketamine treatment were recruited to complete patient rated outcomes measures on sleep quality using the Pittsburgh Sleep Quality Index (PSQI) and circadian rhythm using the Morningness–Eveningness Questionnaire (MEQ). Over a 4-week course of eight ketamine infusions, reports were obtained at baseline (T0), prior to second treatment (T1), prior to fifth treatment (T2), and 1 week after eighth treatment (T3).

Results

Forty participants with TRD (mean age = 42.8, 45% male) were enrolled. Twenty-nine (72.5%) had complete follow-up data. Paired t tests revealed statistically significant improvements at the end of treatment in sleep quality (PSQI) ( p = 0.003) and depressive symptoms (Clinically Useful Depression Outcome Scale-Depression, p < 0.001) while circadian rhythm (MEQ) shifted earlier ( p = 0.007). The PSQI subscale components of sleep duration ( p = 0.008) and daytime dysfunction ( p = 0.001) also improved. In an exploratory post hoc analysis, ketamine’s impact on sleep quality was more prominent in patients with mixed features, while its chronobiotic effect was prominent in those without mixed features.

Conclusion

IV ketamine may improve sleep quality and advance circadian rhythm in individuals with TRD. Effects may differ in individuals with mixed features of depression as compared to those without. Since this was a small uncontrolled study, future research is warranted.

Schlagwörter

Stichwörter der Autor:innen

circadian rhythminsomniaketaminepatient-reported outcomessleep qualitytreatment-resistant depression

Autor:innen und Institutionen

  • Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada.
  • Department of Medicine, University of Calgary, Canada.
  • Cabrini Center, 3rd Floor, 16811-88 Ave NW, Edmonton, AB, Canada T5R 5YR.
  • Department of Psychiatry, University of Alberta, Canada.
  • Misericordia Community Hospital, Edmonton, Alberta, Canada.

ORCID-Profile: Jennifer Swainson

Förderung

  • University of Alberta Dept of Psychiatry

Zitieren

APA

Yan, R., Marshall, T., Khullar, A., Nagle, T., Knowles, J., Malkin, M., Chubbs, B., & Swainson, J. (2024). Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression. Therapeutic Advances in Psychopharmacology, 14. https://doi.org/10.1177/20451253241231264

Vancouver

Yan R, Marshall T, Khullar A, Nagle T, Knowles J, Malkin M, et al. Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression. Therapeutic Advances in Psychopharmacology. 2024;14. doi:10.1177/20451253241231264

BibTeX
@article{Yan2024,
  author = {Yan, Raymond and Marshall, Tyler and Khullar, Atul and Nagle, Travis and Knowles, Jake and Malkin, Mai and Chubbs, Brittany and Swainson, Jennifer},
  title = {Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression},
  journal = {Therapeutic Advances in Psychopharmacology},
  year = {2024},
  volume = {14},
  doi = {10.1177/20451253241231264}
}
Kostenlos starten →